RYBIX ODT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for RYBIX ODT (RYBIX ODT).
Rybix ODT (tramadol hydrochloride) is a centrally acting synthetic opioid analgesic. It binds to μ-opioid receptors and inhibits the reuptake of serotonin and norepinephrine, modulating pain pathways in the central nervous system.
| Metabolism | Primarily metabolized by CYP2D6 and CYP3A4 to active and inactive metabolites. Tramadol is O-demethylated to M1 (active) via CYP2D6 and N-demethylated to M2 via CYP3A4. M1 is further conjugated. |
| Excretion | Renal excretion of unchanged drug accounts for approximately 30-40% of elimination. Biliary/fecal excretion is the primary route, with 50-65% recovered in feces as unchanged drug and metabolites. Minor metabolism via CYP3A4 contributes to elimination. |
| Half-life | Terminal elimination half-life is approximately 12-15 hours in adults with normal renal and hepatic function. This supports twice-daily dosing. Half-life may be prolonged in severe hepatic impairment. |
| Protein binding | Approximately 99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is approximately 1.0-1.5 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Absolute bioavailability of the orally disintegrating tablet is approximately 30-40% due to first-pass metabolism. Food does not significantly affect bioavailability. |
| Onset of Action | Orally disintegrating tablet: Onset of clinical effect (reduction in dyskinesia) occurs within 30-60 minutes. Peak effect at 1-2 hours. |
| Duration of Action | Duration of clinical effect is approximately 4-6 hours, with wearing-off observed at end of dosing interval. Twice-daily dosing maintains therapeutic levels. |
50 to 100 mg orally twice daily; maximum dose 200 mg per day.
| Dosage form | TABLET, ORALLY DISINTEGRATING |
| Renal impairment | GFR 30-59 mL/min: 50 mg twice daily. GFR 15-29 mL/min: 50 mg once daily. GFR <15 mL/min: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: 50 mg twice daily. Child-Pugh C: 50 mg once daily. |
| Pediatric use | Not approved for use in pediatric patients; safety and efficacy not established. |
| Geriatric use | Start at 25 mg twice daily; titrate slowly due to increased sensitivity and risk of adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for RYBIX ODT (RYBIX ODT).
| Breastfeeding | Excreted in human milk in small amounts; milk-to-plasma ratio approximately 0.5. Use caution due to potential for infant sedation or respiratory depression. American Academy of Pediatrics considers compatible with breastfeeding, but monitor infant for excessive drowsiness or feeding difficulties. |
| Teratogenic Risk | Pregnancy Category C: Animal reproduction studies have shown an increased incidence of fetal abnormalities (cleft palate, skeletal malformations) at doses equivalent to human doses. There are no adequate and well-controlled studies in pregnant women. Use during first trimester is associated with potential risk of congenital malformations. In second and third trimesters, risk of decreased fetal heart rate or neonatal respiratory depression. |
■ FDA Black Box Warning
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; ultra-rapid metabolizers of CYP2D6 substrates (increased risk of toxicity); interactions with drugs affecting CYP2D6 and CYP3A4.
| Serious Effects |
Hypersensitivity to tramadol or any component of the formulation; significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected gastrointestinal obstruction (including paralytic ileus); concurrent use of MAOIs (or within 14 days of such therapy); use in children <12 years of age; use in children <18 years of age for post-tonsillectomy/adenoidectomy pain management.
| Precautions | Respiratory depression; seizures (increased risk with history of epilepsy, head injury, metabolic disorders, or concomitant serotonergic drugs); serotonin syndrome (especially with SSRIs, SNRIs, MAOIs); increased intracranial pressure; severe hypotension; risk of suicide in patients with depression; use in ultra-rapid metabolizers; withdrawal; drug dependence; risk of adrenal insufficiency; severe skin reactions; interference with laboratory tests; not recommended for use in patients with significant respiratory depression, acute or severe bronchial asthma, or known or suspected gastrointestinal obstruction. |
Loading safety data…
| Fetal Monitoring | Monitor maternal vital signs, sedation level, respiratory rate. In late pregnancy, monitor fetal heart rate and uterine activity. Assess neonatal respiratory status and alertness postpartum. |
| Fertility Effects | No adequate studies on human fertility. In animal studies, no significant impairment of fertility at therapeutic doses. May affect menstrual cycle due to CNS depressant properties. |